ALFA Finder| Revenue growth | H2FY26 revenue up 23.1% YoY to ₹41.6 Cr. |
|---|---|
| Margins | EBITDA margin surged 2625 bps HoH to 26.32% in H2. |
| Demand visibility | Strong sales momentum returned in H2 with restored customer demand. |
| Management confidence | High; cited decisive rebound after intentional H1 credit tightening. |
Growth
H2FY26 revenue grew 23.1% YoY and 64.4% HoH. FY26 annual revenue reached ₹66.9 Cr, up 8.6% YoY.
Outlook
Targeting 500 standardized Xelix clinics by expanding into skin and body aesthetics verticals from a hair-first focus.
Risks
Historically high inventory and credit-driven sales softened H1 performance; regulatory shifts during private-to-public conversion.
Earnings Call filed with NSE, NSE: AAKAAR. Summary written with AI assistance from the document.
Aakaar Medical Technologies Ltd: key numbers
- Share price
- ₹72.00
- Market cap
- ₹102.0 Cr
- Revenue (annual)
- ₹66.96 Cr
- Net profit (annual)
- ₹6.64 Cr
- P/E (TTM)
- 15.4×Sector 54.5×
- Promoter holding
- 67.05%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aakaar Medical Technologies Ltd
All →Aakaar Medical Technologies Annual General Meeting
Aakaar Medical Technologies issued a Postal Ballot Notice seeking approval to appoint Mr. Abhash Meswani as Whole-Time Director with ₹50 lakh annual remuneration for five years.
Aakaar Medical Technologies Earnings Call Transcript: Key Takeaways
H1 FY27 revenue of ₹43.72 Cr (+72.64% YoY) and PAT of ₹3.54 Cr versus a prior loss. Margins were deliberately sacrificed for marketing and the distributor transition. Debtor days (219) and cash (₹1.05 Cr) are the key weak spots.
- Call
- Guides 36% growth
Aakaar Medical Technologies H1 FY27 Results: Turns Profitable, Net Profit ₹3.5 Cr
Aakaar Medical Technologies Ltd reported revenue from operations of ₹43.7 Cr (+72.7% YoY) and net profit of ₹3.5 Cr for H1 FY27.
- Key figure
- Net profit ₹3.5 Cr
Aakaar Medical Technologies Investor Presentation: Key Takeaways
H1 FY27 revenue ₹43.72 Cr (+72.6% YoY), EBITDA ₹5.43 Cr (12.42%), PAT ₹3.54 Cr vs prior loss ₹0.78 Cr. Strategy: doctor-led B2B2C distribution, Xelix clinic network, debtor-days reduction.
Aakaar Medical Technologies Board Meeting Date
Aakaar Medical Technologies Limited will hold a board meeting on 30-Oct-2026 to consider unaudited half-yearly financial results and ESOP matters.
Aakaar Medical Technologies Other Announcement
Aakaar Medical Technologies Limited submitted its Reconciliation of Share Capital Audit Report for the quarter ended September 30, 2026. The report confirms total issued capital remains at 1,41,72,816 equity shares.